Sweeping policy changes under US Secretary of Health and Human Services Robert F. Kennedy Jr are having a chilling effect on vaccine makers as anti-vaccine rhetoric has turned into concrete changes in inoculation schedules and recommendations, investors and executives said.
The administration of US President Donald Trump has in the past year upended vaccine recommendations, with the country last month ending its longstanding guidance that all children receive inoculations against flu, hepatitis A and other diseases.
The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a drag that would likely dent revenues and raise costs for companies in the coming years, investors and analysts said.
Photo: Reuters
“Vaccines will not be a growth area under the current administration,” ING global pharma and healthcare lead Stephen Farrelly said, signaling a potential drag on the sector through 2028.
Kennedy, a longtime anti-vaccine activist who has cast doubt on the safety and efficacy of vaccines contrary to scientific evidence, has moved quickly since taking over the health department.
He fired a panel of independent expert advisers, replacing them with members who share his anti-vaccine views, and dropped broad COVID-19 vaccine recommendations for pregnant women and children.
He also revived research into a long-ago debunked claim linking vaccines to autism, and adopted new reduced childhood vaccine schedules without the long-standing practice of involving a broad group of outside experts.
Investors are concerned the impact of Kennedy’s policies would be hard to reverse, echoing public health experts’ worries, who also said they would lead to preventable illnesses and deaths.
Kennedy said the changes aim to improve safety and bring US vaccine policy in line with other peer nations.
The striking policy changes have begun to prompt some rare public rebukes from industry leaders.
Pfizer CEO Albert Bourla and Sanofi CEO Paul Hudson criticized Kennedy’s rhetoric at a major healthcare conference last week, with Hudson citing “all the... misinformation that is going around.”
Bourla told reporters it was driving down vaccination rates and increasing disease risk.
“I’m seriously frustrated,” he said. “What is happening has zero scientific merit and is just serving an agenda which is political and antivax.”
The long-term prospects for vaccine makers remains robust, as vaccines are still the most effective tool for preventing disease, investors said, but added that companies were now more beholden to the whims of political leaders.
“Unfortunately, success and failure will rest on the opinions of a few people. It’s not enough to have good science and commercial opportunity,” Clear Street analyst Bill Maughan said. “If you’re a biotech investor, it just seems tough to really get conviction in a vaccine name right now.”
Investors said they would stick by large-cap drugmakers less dependent on vaccine revenue such as GSK, Sanofi, Pfizer and Merck. Smaller players such as Moderna, BioNTech and Novavax face sharper risks.
The effect of US changes are already starting to take hold. GSK and Sanofi reported lower US flu vaccine sales in the third quarter, despite a more severe flu season.
In October last year, Australia’s CSL postponed separating its vaccine unit Seqirus, citing “heightened volatility” and falling US vaccination rates.
Some investors said demand for vaccines and disease prevention would likely rebound.
Outbreaks such as the rising measles cases in South Carolina, or an extended severe flu season, could drive renewed vaccine usage, they said.
The US Centers for Disease Control and Prevention said the 2025-2026 flu season had seen at least 11 million cases and 5,000 deaths reported so far, nearly double last year’s toll.
Medical organizations, including the American Academy of Pediatrics, have challenged Kennedy’s policies in court and it remains to be seen how that would play out.
Investors “often focus on shorter-term time frames, while companies clearly take a far longer-term view,” Candriam senior portfolio manager Linden Thomson said.
“These businesses have been around for decades. They don’t invest on a one- or two-year horizon,” said Matthew Masucci, an analyst for Callodine Capital, which owns GSK and Sanofi shares.
For now, investors might be more cautious.
KEEPING UP: The acquisition of a cleanroom in Taiwan would enable Micron to increase production in a market where demand continues to outpace supply, a Micron official said Micron Technology Inc has signed a letter of intent to buy a fabrication site in Taiwan from Powerchip Semiconductor Manufacturing Corp (力積電) for US$1.8 billion to expand its production of memory chips. Micron would take control of the P5 site in Miaoli County’s Tongluo Township (銅鑼) and plans to ramp up DRAM production in phases after the transaction closes in the second quarter, the company said in a statement on Saturday. The acquisition includes an existing 12 inch fab cleanroom of 27,871m2 and would further position Micron to address growing global demand for memory solutions, the company said. Micron expects the transaction to
Nvidia Corp’s GB300 platform is expected to account for 70 to 80 percent of global artificial intelligence (AI) server rack shipments this year, while adoption of its next-generation Vera Rubin 200 platform is to gradually gain momentum after the third quarter of the year, TrendForce Corp (集邦科技) said. Servers based on Nvidia’s GB300 chips entered mass production last quarter and they are expected to become the mainstay models for Taiwanese server manufacturers this year, Trendforce analyst Frank Kung (龔明德) said in an interview. This year is expected to be a breakout year for AI servers based on a variety of chips, as
Global semiconductor stocks advanced yesterday, as comments by Nvidia Corp chief executive officer Jensen Huang (黃仁勳) at Davos, Switzerland, helped reinforce investor enthusiasm for artificial intelligence (AI). Samsung Electronics Co gained as much as 5 percent to an all-time high, helping drive South Korea’s benchmark KOSPI above 5,000 for the first time. That came after the Philadelphia Semiconductor Index rose more than 3 percent to a fresh record on Wednesday, with a boost from Nvidia. The gains came amid broad risk-on trade after US President Donald Trump withdrew his threat of tariffs on some European nations over backing for Greenland. Huang further
HSBC Bank Taiwan Ltd (匯豐台灣商銀) and the Taiwan High Prosecutors Office recently signed a memorandum of understanding (MOU) to enhance cooperation on the suspicious transaction analysis mechanism. This landmark agreement makes HSBC the first foreign bank in Taiwan to establish such a partnership with the High Prosecutors Office, underscoring its commitment to active anti-fraud initiatives, financial inclusion, and the “Treating Customers Fairly” principle. Through this deep public-private collaboration, both parties aim to co-create a secure financial ecosystem via early warning detection and precise fraud prevention technologies. At the signing ceremony, HSBC Taiwan CEO and head of banking Adam Chen (陳志堅)
RSS